Free Trial

Arvinas Q4 2024 Earnings Report

Arvinas logo
$7.59 -0.45 (-5.60%)
As of 03/28/2025 04:00 PM Eastern

Arvinas EPS Results

Actual EPS
-$0.63
Consensus EPS
-$1.07
Beat/Miss
Beat by +$0.44
One Year Ago EPS
-$2.53

Arvinas Revenue Results

Actual Revenue
N/A
Expected Revenue
$62.79 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Arvinas Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Arvinas Earnings Headlines

Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Here's Why
FY2025 EPS Estimates for Arvinas Raised by Cantor Fitzgerald
See More Arvinas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email.

About Arvinas

Arvinas (NASDAQ:ARVN), a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

View Arvinas Profile

More Earnings Resources from MarketBeat